The drugmaker Pfizer is no longer developing a daily anti-obesity pill, setting back efforts to find new ways to treat obesity that don’t involve regular injections.
The company said it would stop studying the experimental drug, danuglipron, after a participant in one of its clinical trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.
